EZH2 and/or PRC2 have been the focus for targeted inhibition due to their documented altered activity and levels in several tumor types including prostate, glioblastoma, B-cell lymphoma and multiple myeloma [77,78] and the suggestion that the associated H3K27me3 profile may confer stemness properties not only in human embryonic stem cells, but also in cancer cells. Here, EZH2 is linked to AL amyloidosis.